{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:11:37Z","timestamp":1792782697340,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Pharma AG"},{"DOI":"10.13039\/501100018936","name":"Universit\u00e4tsklinikum Heidelberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018936","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN) are ultra-rare chronic kidney diseases with an overall poor prognosis, with approximately 40\u201350% of patients progressing to kidney failure within 10\u00a0years of diagnosis. C3G is characterized by a high rate of disease recurrence in the transplanted kidney. However, there is a lack of published data on clinical outcomes in the pediatric population following transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this multicenter longitudinal cohort study of the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN) registry, we compared the post-transplant outcomes of pediatric patients with C3G (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200917) or IC-MPGN (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093) with a matched case\u2013control group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200920).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eleven of 20 children (55%) with C3G or IC-MPGN experienced a recurrence within 5\u00a0years post-transplant. Patients with C3G or IC-MPGN had a 5-year graft survival of 61.4%, which was significantly (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.029) lower than the 5-year graft survival of 90% in controls; five patients with C3G or IC-MPGN lost their graft due to recurrence during this observation period. Both the 1-year (20%) and the 5-year (42%) rates of biopsy-proven acute rejection episodes were comparable between patients and controls. Complement-targeted therapy with eculizumab, either as prophylaxis or treatment, did not appear to be effective.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These data in pediatric patients with C3G or IC-MPGN show a high risk of post-transplant disease recurrence (55%) and a significantly lower 5-year graft survival compared to matched controls with other primary kidney diseases. These data underscore the need for post-transplant patients for effective and specific therapies that target the underlying disease mechanism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00467-024-06476-5","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T07:07:15Z","timestamp":1723014435000},"page":"3569-3580","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Kidney transplantation in children and adolescents with C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis: a real-world study within the CERTAIN research network"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1270-6508","authenticated-orcid":false,"given":"Christian","family":"Patry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J. A.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5016-9731","authenticated-orcid":false,"given":"Manuel","family":"Fei\u00dft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0409-5196","authenticated-orcid":false,"given":"Kai","family":"Krupka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2929-8085","authenticated-orcid":false,"given":"Jan","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3378-2160","authenticated-orcid":false,"given":"Martin","family":"Bald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7011-302X","authenticated-orcid":false,"given":"Benedetta","family":"Antoniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4852-989X","authenticated-orcid":false,"given":"Ilmay","family":"Bilge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0236-5786","authenticated-orcid":false,"given":"Bora","family":"Gulhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nele","family":"Kanzelmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0198-1221","authenticated-orcid":false,"given":"Ozan","family":"Ozkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"B\u00fcscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9902-0850","authenticated-orcid":false,"given":"Anne-Laure","family":"Sellier-Leclerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4116-598X","authenticated-orcid":false,"given":"Lutz T.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9939-4059","authenticated-orcid":false,"given":"Alexander","family":"Fichtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4131-2273","authenticated-orcid":false,"given":"Britta","family":"H\u00f6cker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6598-6910","authenticated-orcid":false,"given":"Burkhard","family":"T\u00f6nshoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"6476_CR1","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1159\/000507254","volume":"144","author":"F Caravaca-Font\u00e1n","year":"2020","unstructured":"Caravaca-Font\u00e1n F, Lucientes L, Cavero T, Praga M (2020) Update on C3 glomerulopathy: a complement-mediated disease. Nephron 144:272\u2013280. https:\/\/doi.org\/10.1159\/000507254","journal-title":"Nephron"},{"key":"6476_CR2","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1681\/ASN.2015060612","volume":"27","author":"S Sethi","year":"2016","unstructured":"Sethi S, Haas M, Markowitz GS et al (2016) Mayo clinic\/renal pathology society consensus report on pathologic classification, diagnosis, and reporting of GN. J Am Soc Nephrol 27:1278\u20131287. https:\/\/doi.org\/10.1681\/ASN.2015060612","journal-title":"J Am Soc Nephrol"},{"key":"6476_CR3","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00467-011-2059-7","volume":"27","author":"DF Lu","year":"2012","unstructured":"Lu DF, Moon M, Lanning LD et al (2012) Clinical features and outcomes of 98 children and adults with dense deposit disease. Pediatr Nephrol 27:773\u2013781. https:\/\/doi.org\/10.1007\/s00467-011-2059-7","journal-title":"Pediatr Nephrol"},{"key":"6476_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2215\/CJN.04700513","volume":"9","author":"NR Medjeral-Thomas","year":"2014","unstructured":"Medjeral-Thomas NR, O\u2019Shaughnessy MM, O\u2019Regan JA et al (2014) C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol 9:46\u201353. https:\/\/doi.org\/10.2215\/CJN.04700513","journal-title":"Clin J Am Soc Nephrol"},{"key":"6476_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2215\/CJN.03480708","volume":"4","author":"SH Nasr","year":"2009","unstructured":"Nasr SH, Valeri AM, Appel GB et al (2009) Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol 4:22\u201332. https:\/\/doi.org\/10.2215\/CJN.03480708","journal-title":"Clin J Am Soc Nephrol"},{"key":"6476_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00467-015-3310-4","volume":"32","author":"M Riedl","year":"2017","unstructured":"Riedl M, Thorner P, Licht C (2017) C3 glomerulopathy. Pediatr Nephrol 32:43\u201357","journal-title":"Pediatr Nephrol"},{"key":"6476_CR7","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/ki.2012.63","volume":"82","author":"A Servais","year":"2012","unstructured":"Servais A, No\u00ebl LH, Roumenina LT et al (2012) Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 82:454\u2013464. https:\/\/doi.org\/10.1038\/ki.2012.63","journal-title":"Kidney Int"},{"key":"6476_CR8","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1681\/ASN.2007030356","volume":"18","author":"RJH Smith","year":"2007","unstructured":"Smith RJH, Alexander J, Barlow PN et al (2007) New approaches to the treatment of dense deposit disease. J Am Soc Nephrol 18:2447\u20132456. https:\/\/doi.org\/10.1681\/ASN.2007030356","journal-title":"J Am Soc Nephrol"},{"key":"6476_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2024.100839","volume":"38","author":"S Obata","year":"2024","unstructured":"Obata S, Vaz de Castro PAS, Riella LV, Cravedi P (2024) Recurrent C3 glomerulopathy after kidney transplantation. Transplant Rev 38:100839","journal-title":"Transplant Rev"},{"key":"6476_CR10","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.2215\/CJN.07110810","volume":"6","author":"S Sethi","year":"2011","unstructured":"Sethi S, Fervenza FC, Zhang Y et al (2011) Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin J Am Soc Nephrol 6:1009\u20131017. https:\/\/doi.org\/10.2215\/CJN.07110810","journal-title":"Clin J Am Soc Nephrol"},{"key":"6476_CR11","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/nejmra1108178","volume":"366","author":"S Sethi","year":"2012","unstructured":"Sethi S, Fervenza FC (2012) Membranoproliferative glomerulonephritis \u2014 a new look at an old entity. N Engl J Med 366:1119\u20131131. https:\/\/doi.org\/10.1056\/nejmra1108178","journal-title":"N Engl J Med"},{"key":"6476_CR12","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1053\/j.ajkd.2020.11.011","volume":"77","author":"F Caravaca-Font\u00e1n","year":"2021","unstructured":"Caravaca-Font\u00e1n F, Trujillo H, Alonso M et al (2021) Validation of a histologic scoring index for C3 glomerulopathy. Am J Kidney Dis 77:684-695.e1. https:\/\/doi.org\/10.1053\/j.ajkd.2020.11.011","journal-title":"Am J Kidney Dis"},{"key":"6476_CR13","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.2215\/CJN.00320121","volume":"16","author":"EKS Wong","year":"2021","unstructured":"Wong EKS, Marchbank KJ, Lomax-Browne H et al (2021) C3 glomerulopathy and related disorders in children etiology-phenotype correlation and outcomes. Clin J Am Soc Nephrol 16:1639\u20131651. https:\/\/doi.org\/10.2215\/CJN.00320121","journal-title":"Clin J Am Soc Nephrol"},{"key":"6476_CR14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.molimm.2016.01.010","volume":"71","author":"P Iatropoulos","year":"2016","unstructured":"Iatropoulos P, Noris M, Mele C et al (2016) Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol 71:131\u2013142. https:\/\/doi.org\/10.1016\/j.molimm.2016.01.010","journal-title":"Mol Immunol"},{"key":"6476_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1681\/ASN.2017030258","volume":"29","author":"P Iatropoulos","year":"2018","unstructured":"Iatropoulos P, Daina E, Curreri M et al (2018) Cluster analysis identifies distinct pathogenetic patterns in c3 glomerulopathies\/immune complex\u2013mediated membranoproliferative GN. J Am Soc Nephrol 29:283\u2013294. https:\/\/doi.org\/10.1681\/ASN.2017030258","journal-title":"J Am Soc Nephrol"},{"key":"6476_CR16","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1093\/ckj\/sfz073","volume":"13","author":"N Garam","year":"2019","unstructured":"Garam N, Proh\u00e1szka Z, Szil\u00e1gyi \u00c1 et al (2019) Validation of distinct pathogenic patterns in a cohort of membranoproliferative glomerulonephritis patients by cluster analysis. Clin Kidney J 13:225\u2013234. https:\/\/doi.org\/10.1093\/ckj\/sfz073","journal-title":"Clin Kidney J"},{"key":"6476_CR17","doi-asserted-by":"publisher","first-page":"e13597","DOI":"10.1111\/petr.13597","volume":"23","author":"A Chua","year":"2019","unstructured":"Chua A, Cramer C, Moudgil A et al (2019) Kidney transplant practice patterns and outcome benchmarks over 30 years: the 2018 report of the NAPRTCS. Pediatr Transplant 23:e13597. https:\/\/doi.org\/10.1111\/petr.13597","journal-title":"Pediatr Transplant"},{"key":"6476_CR18","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.transproceed.2013.01.007","volume":"45","author":"L Plotnicki","year":"2013","unstructured":"Plotnicki L, Kohl CD, H\u00f6cker B et al (2013) The CERTAIN registry: a novel, web-based registry and research platform for pediatric renal transplantation in Europe. Transplant Proc 45:1414\u20131417. https:\/\/doi.org\/10.1016\/j.transproceed.2013.01.007","journal-title":"Transplant Proc"},{"key":"6476_CR19","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1097\/TP.0000000000002414","volume":"103","author":"B H\u00f6cker","year":"2019","unstructured":"H\u00f6cker B, Schneble L, Murer L et al (2019) Epidemiology of and risk factors for BK polyomavirus replication and nephropathy in pediatric renal transplant recipients: an international CERTAIN registry study. Transplantation 103:1224\u20131233. https:\/\/doi.org\/10.1097\/TP.0000000000002414","journal-title":"Transplantation"},{"key":"6476_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF et al (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629\u2013637. https:\/\/doi.org\/10.1681\/ASN.2008030287","journal-title":"J Am Soc Nephrol"},{"key":"6476_CR21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1093\/ndt\/gfac148","volume":"38","author":"F Caravaca-Font\u00e1n","year":"2023","unstructured":"Caravaca-Font\u00e1n F, Polanco N, Villacorta B et al (2023) Recurrence of immune complex and complement-mediated membranoproliferative glomerulonephritis in kidney transplantation. Nephrol Dial Transplant 38:222\u2013235. https:\/\/doi.org\/10.1093\/ndt\/gfac148","journal-title":"Nephrol Dial Transplant"},{"key":"6476_CR22","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1681\/ASN.2013070715","volume":"25","author":"L Zand","year":"2014","unstructured":"Zand L, Lorenz EC, Cosio FG et al (2014) Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. J Am Soc Nephrol 25:1110\u20131117. https:\/\/doi.org\/10.1681\/ASN.2013070715","journal-title":"J Am Soc Nephrol"},{"key":"6476_CR23","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/ndt\/gfs549","volume":"28","author":"KJ Van Stralen","year":"2013","unstructured":"Van Stralen KJ, Verrina E, Belingheri M et al (2013) Impact of graft loss among kidney diseases with a high risk of post-transplant recurrence in the paediatric population. Nephrol Dial Transplant 28:1031\u20131038. https:\/\/doi.org\/10.1093\/ndt\/gfs549","journal-title":"Nephrol Dial Transplant"},{"issue":"4S","key":"6476_CR24","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Adler SG, Barratt J et al (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100(4S):S1\u2013S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"key":"6476_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2024.05.015","author":"M Vivarelli","year":"2024","unstructured":"Vivarelli M, Barratt J, Beck LH Jr et al (2024) The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. https:\/\/doi.org\/10.1016\/j.kint.2024.05.015","journal-title":"Kidney Int"},{"key":"6476_CR26","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1182\/bloodadvances.2022009129","volume":"7","author":"RSM Wong","year":"2023","unstructured":"Wong RSM, Navarro-Cabrera JR, Comia NS et al (2023) Pegcetacoplan controls hemolysis in complement inhibitor\u2013naive patients with paroxysmal nocturnal hemoglobinuria. Blood Adv 7:2468\u20132478. https:\/\/doi.org\/10.1182\/bloodadvances.2022009129","journal-title":"Blood Adv"},{"key":"6476_CR27","doi-asserted-by":"publisher","first-page":"7926","DOI":"10.1073\/pnas.1820892116","volume":"116","author":"A Schubart","year":"2019","unstructured":"Schubart A, Anderson K, Mainolfi N et al (2019) Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A 116:7926\u20137931. https:\/\/doi.org\/10.1073\/pnas.1820892116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6476_CR28","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1007\/s00467-023-06035-4","volume":"38","author":"F Zotta","year":"2023","unstructured":"Zotta F, Diomedi-Camassei F, Gargiulo A et al (2023) Successful treatment with avacopan (CCX168) in a pediatric patient with C3 glomerulonephritis. Pediatr Nephrol 38:4197\u20134201. https:\/\/doi.org\/10.1007\/s00467-023-06035-4","journal-title":"Pediatr Nephrol"},{"key":"6476_CR29","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1016\/j.ekir.2023.09.017","volume":"8","author":"E Wong","year":"2023","unstructured":"Wong E, Nester C, Cavero T et al (2023) Efficacy and safety of iptacopan in patients with C3 glomerulopathy. Kidney Int Rep 8:2754\u20132764. https:\/\/doi.org\/10.1016\/j.ekir.2023.09.017","journal-title":"Kidney Int Rep"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06476-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-024-06476-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-024-06476-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T07:07:39Z","timestamp":1729840059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-024-06476-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6476"],"URL":"https:\/\/doi.org\/10.1007\/s00467-024-06476-5","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]},"assertion":[{"value":"30 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nicholas JA Webb and Matthias Meier are employees of Novartis, Basel, Switzerland. Burkhard T\u00f6nshoff has received research grants from Novartis, Astellas, and Chiesi, and consulting fees from Bristol-Myers Squibb, CSL Behring Biotherapies for Life, Vifor, and Chiesi. Lutz T. Weber has received research grants from Chiesi and lecture fees from Novartis, Alexion, and Chiesi. Jan U. Becker counsels Sanofi. Martin Bald received sponsoring for congress from Novartis and Alexion and speaker fees from Alexion.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}